PharmAthene Newswire

PharmAthene Newswire

Comprehensive Real-Time News Feed for PharmAthene.

Results 1 - 20 of 44 in PharmAthene

  1. PharmAthene, Inc. - Mergers & Acquisitions (M&A), Partnerships &...Read the original story

    Monday Jun 22 | PR-inside.com

    Report Features MarketLines' PharmAthene, Inc. Mergers & Acquisitions , Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions , divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by PharmAthene, Inc. since January 2007. Scope of the Report * Provides intelligence on PharmAthene, Inc.'s M&A, strategic partnerships and alliances, capital raising and private equity transactions.

    Comment?

  2. PharmAthene Short Interest Down 2.9% in MayRead the original story w/Photo

    Wednesday Jun 10 | AmericanBankingNews.com

    Shares of PharmAthene were the target of a significant drop in short interest in May. As of May 29th, there was short interest totalling 2,090,928 shares, a drop of 2.9% from the May 15th total of 2,154,373 shares, Marketbeat.com reports. Currently, 3.7% of the shares of the company are sold short.

    Comment?

  3. Short Interest in PharmAthene Declines By 0.0%Read the original story w/Photo

    May 31, 2015 | AmericanBankingNews.com

    Shares of PharmAthene were the recipient of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 2,154,373 shares, a drop of 0.0% from the April 30th total of 2,155,360 shares, American Banking News reports. Approximately 3.9% of the shares of the stock are sold short.

    Comment?

  4. New Market Report: PharmAthene, Inc. (PIP) - Pharmaceuticals &...Read the original story

    May 25, 2015 | PR-inside.com

    Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions , partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.

    Comment?

  5. PharmAthene Short Interest Down 2.3% in AprilRead the original story w/Photo

    May 13, 2015 | AmericanBankingNews.com

    Shares of PharmAthene were the recipient of a large decline in short interest during the month of April. As of April 30th, there was short interest totalling 2,155,360 shares, a decline of 2.3% from the April 15th total of 2,206,258 shares, StockRatingsNetwork reports.

    Comment?

  6. PharmAthene, Inc. Reports First Quarter 2015 Financial and Operational ResultsRead the original story

    May 7, 2015 | BioSpace

    /PRNewswire/ -- PharmAthene, Inc. (NYSE MKT: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the first quarter of 2015. Highlights during ...

    Comment?

  7. PharmAthene Reports First Quarter 2015 Financial and Operational ResultsRead the original story

    May 7, 2015 | Freshnews

    ANNAPOLIS, Md., May 7, 2015 /PRNewswire/ -- PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the first quarter of 2015.

    Comment?

  8. ITI Appoints Regulatory Affairs VPRead the original story w/Photo

    May 7, 2015 | Contract Pharma Breaking News

    ... has more than 30 years of experience in the regulatory space and has worked both as a consultant and in-house at PharmAthene, Northwest Biotherapeutics, Caris Life Sciences, Guilford Pharmaceuticals and Centocor, where she oversaw regulatory ...

    Comment?

  9. Immunomic Therapeutics Names As Vice President, Regulatory AffairsRead the original story

    May 5, 2015 | BioSpace

    ... space, Ms. Peltier has worked both as a consultant and in-house at such well-known life sciences companies as PharmAthene, Northwest Biotherapeutics, Caris Life Sciences, Guilford Pharmaceuticals and Centocor where she oversaw countless regulatory ...

    Comment?

  10. Air Transport Services Group Inc. (ATSG) and Nature's Sunshine...Read the original story

    Apr 30, 2015 | Insider Monkey

    ... (NASDAQ: NATR ), Regional Management Corp (NYSE: RM ), Servicesource International Inc (NASDAQ: SREV ), and PharmAthene, Inc. (NYSEMKT: PIP ) . Aside from Prescott we have been following over 700 hedge funds at Insider Monkey for the last couple of ...

    Comment?

  11. How legally binding is a letter of intent?Read the original story w/Photo

    Apr 23, 2015 | Investopedia

    ... it of the bargain" damages between two companies in a mergers and acquisitions deal in SIGA Technologies, Inc v. PharmAthene, Inc.

    Comment?

  12. PharmAthene, Inc. Receives $5.8 Million Payment FromRead the original story

    Apr 12, 2015 | BioSpace

    ... "could"; "may"; "should"; "will"; "project"; "potential"; or similar statements are forward-looking statements. PharmAthene disclaims any intent or obligation to update these forward-looking statements other than as required by law. Risks and ...

    Comment?

  13. Boeing: 5% Performance Shortfall Puts 737 MAX In A Difficult PositionRead the original story w/Photo

    Apr 1, 2015 | Seeking Alpha

    Airbus and Boeing both are bringing their new narrow body airframe to the market in the coming years. Both airframes are powered by CFM LEAP engines.

    Comment?

  14. Boeing: 5% Performance Shortfall Puts 737 MAX In A Difficult PositionRead the original story w/Photo

    Apr 1, 2015 | Seeking Alpha

    Airbus and Boeing both are bringing their new narrow body airframe to the market in the coming years. Both airframes are powered by CFM LEAP engines.

    Comment?

  15. SIGA Technologies Receives NASDAQ Delisting NotificationRead the original story

    Mar 18, 2015 | Freshnews

    ... United States Bankruptcy Code. The Company's Chapter 11 filing was precipitated by its ongoing litigation with PharmAthene, Inc. We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and ...

    Comment?

  16. SIGA Technologies Receives NASDAQ Delisting NotificationRead the original story

    Mar 18, 2015 | Business Wire

    ... United States Bankruptcy Code. The Company's Chapter 11 filing was precipitated by its ongoing litigation with PharmAthene, Inc. We are a company specializing in the development and commercialization of solutions for serious unmet medical needs and ...

    Comment?

  17. PharmAthene changes CEO, reduces staffRead the original story

    Mar 10, 2015 | Daily Record

    PharmAthene Inc., an Annapolis-based company that develops biodefense products, is changing its chief executive officer and plans to cut its 11-person staff by two-thirds, the firm announced this week. John M. Gill, a director of PharmAthene for nine years, will replace Eric Richman as president and CEO on Thursday.

    Comment?

  18. PharmAthene, Inc. Reports Year-End 2014 Financial And Operational...Read the original story

    Mar 9, 2015 | BioSpace

    PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended . In addition, the Company announced that its Board of Directors approved a realignment plan to maximize, for its shareholders, the value of any proceeds from its litigation with SIGA Technologies, Inc. and its existing biodefense assets.

    Comment?

  19. PharmAthene Reports Year-End 2014 Financial And Operational Results;...Read the original story

    Mar 9, 2015 | Freshnews

    Delaware Court of Chancery issues final judgment granting lump sum award to PharmAthene totaling approximately $195 million -- NIAID awards contract for next generation anthrax vaccine program -- New non-clinical data demonstrate SparVax provides equivalent protection to BioThrax in head-to-head comparison PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today reported its financial and operational results for the year ended December 31, 2014.

    Comment?

  20. Vaccinogen Elects To Board Of DirectorsRead the original story

    Feb 16, 2015 | BioSpace

    ... with preparing the company for its IPO that resulted in a pre-money valuation of . As CFO and Treasurer for PharmAthene, Inc., a biotechnology company focused on countermeasures to terrorist biological threats, he established financial reporting and ...

    Comment?